Pharmacokinetics and tolerability of single-dose daptomycin in young infants.

BACKGROUND: Daptomycin is approved for the treatment of complicated skin and skin-structure infections and Staphylococcus aureus bacteremia. We sought to characterize daptomycin single-dose pharmacokinetics and tolerability in young infants. METHODS: Subjects < 120 days of age with suspected systemic infections were eligible for inclusion. Each subject was given a single 6 mg/kg intravenous dose of daptomycin. An average of 4 postdose concentrations per infant was obtained. RESULTS: Data from 20 infants are presented. Median gestational age at birth and postnatal age were 32 weeks (range: 23, 40) and 3 days (1, 85), respectively. The median area under the concentration curve at 24 hours, volume of distribution, total body clearance and half-life of daptomycin were 262.4 mg×h/L (166.7, 340.2), 0.21 L/kg (0.11, 0.34), 0.021 L/h/kg (0.016, 0.034) and 6.2 hours (3.7, 9.0), respectively. No adverse events related to daptomycin were observed, including changes in creatine phosphokinase concentrations. CONCLUSIONS: Daptomycin clearance in young infants was similar to that in children 2-6 years of age and higher than that observed in adolescents and adults.

Duke Scholars

Author Michael Cohen-Wolkowiez Pediatrics, Infectious Diseases

Author Christoph Paul Vincent Hornik Pediatrics, Critical Care Medicine

Author Daniel Kelly Benjamin Jr. Pediatrics, Infectious Diseases

Author Phillip Brian Smith Pediatrics, Neonatology